Calidi Biotherapeutics (CLDI) Net Income towards Common Stockholders (2022 - 2025)
Calidi Biotherapeutics' quarterly Net Income towards Common Stockholders came in at -$4.1 million in Q4 2025, up 1.0% year-on-year from -$4.0 million in Q4 2024, and up 62.52% quarter-over-quarter from -$10.8 million in Q3 2025.
Calidi Biotherapeutics has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$4.1 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 1.0% year-over-year to -$4.1 million; the trailing twelve-month figure through Dec 2025 stood at -$25.6 million (down 7.41% YoY), and the FY2025 full-year result was -$25.6 million, down 7.41% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$4.1 million, up from -$10.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $4.2 million in Q2 2022, with the low at -$12.5 million in Q2 2023.
- Average Net Income towards Common Stockholders over 4 years is -$5.4 million, with a median of -$5.5 million recorded in 2022.
- Peak annual rise in Net Income towards Common Stockholders reached 62.2% in 2023, while the deepest fall reached 541.94% in 2023.
- Tracing CLDI's Net Income towards Common Stockholders over 4 years: stood at -$7.8 million in 2022, then slipped by 5.91% to -$8.2 million in 2023, then jumped by 50.21% to -$4.1 million in 2024, then climbed by 1.0% to -$4.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$4.1 million (Q4 2025), -$10.8 million (Q3 2025), and -$5.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | -4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.06 Mn |
| Sep 30, 2025 | -10.82 Mn |
| Jun 30, 2025 | -5.72 Mn |
| Mar 31, 2025 | -4.99 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -5.05 Mn |
| Jun 30, 2024 | -7.44 Mn |
| Mar 31, 2024 | -7.23 Mn |
| Dec 31, 2023 | -8.23 Mn |
| Sep 30, 2023 | -2.02 Mn |
| Jun 30, 2023 | -12.50 Mn |
| Mar 31, 2023 | -6.46 Mn |
| Dec 31, 2022 | -7.77 Mn |
| Sep 30, 2022 | -5.35 Mn |
| Jun 30, 2022 | 4.16 Mn |
| Mar 31, 2022 | 1.46 Mn |